Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression

被引:206
作者
Artham, Surya M. [1 ]
Lavie, Carl J. [1 ]
Milani, Richard V. [1 ]
Patel, Dharmendrakumar A. [1 ]
Verma, Anil [1 ]
Ventura, Hector O. [1 ]
机构
[1] Ochsner Med Ctr, New Orleans, LA 70121 USA
关键词
END-POINT REDUCTION; ONSET ATRIAL-FIBRILLATION; CONGESTIVE-HEART-FAILURE; SUDDEN CARDIAC DEATH; LOSARTAN INTERVENTION; HYPERTENSIVE PATIENTS; ANTIHYPERTENSIVE TREATMENT; ANGIOTENSIN-II; BLOOD-PRESSURE; RISK-FACTOR;
D O I
10.1016/j.pcad.2009.05.002
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Left ventricular hypertrophy (LVH) is an independent risk factor and predictor of cardiovascular (CV) events and all-cause mortality. Patients with LVH are at increased risk for stroke, congestive heart failure, coronary heart disease, and sudden cardiac death. Left ventricular hypertrophy represents both a manifestation of the effects of hypertension and other CV risk factors over time as well as an intrinsic condition causing pathologic changes in the CV structure and function. We review the risk factors for LVH and its consequences, concentric remodeling, and its prognostic significance, clinical benefits and supporting evidence for LVH regression, and its implications for management. We conclude our review summarizing the various pharmacological and nonpharmacological therapeutic options approved for the treatment of hypertension and LVH regression and the supporting clinical trial data for these therapeutic strategies. © 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:153 / 167
页数:15
相关论文
共 115 条
[1]
[Anonymous], ARCH INTERN MED, DOI DOI 10.1001/ARCHINTE.1962.03620200090016
[2]
USEFULNESS OF ECHOCARDIOGRAPHIC LEFT-VENTRICULAR HYPERTROPHY, VENTRICULAR-TACHYCARDIA AND COMPLEX VENTRICULAR ARRHYTHMIAS IN PREDICTING VENTRICULAR-FIBRILLATION OR SUDDEN CARDIAC DEATH IN ELDERLY PATIENTS [J].
ARONOW, WS ;
EPSTEIN, S ;
KOENIGSBERG, M ;
SCHWARTZ, KS .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (16) :1124-1125
[3]
Cardiovascular risk factors in hypertension: Rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile [J].
Bakris, George L. ;
Tarka, Elizabeth A. ;
Waterhouse, Brian ;
Goulding, Michelle R. ;
Madan, Anuradha ;
Anderson, Karen M. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (7A) :46L-52L
[4]
Beevers G., 2014, ABC OF HYPERTENSION
[5]
Berglund T, 2008, J HYPERTENS, V26, pS254
[6]
The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events [J].
Bluemke, David A. ;
Kronmal, Richard A. ;
Lima, Joao A. C. ;
Liu, Kiang ;
Olson, Jean ;
Burke, Gregory L. ;
Folsom, Aaron R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (25) :2148-2155
[7]
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study [J].
Boner, G ;
Cooper, ME ;
McCarroll, K ;
Brenner, BM ;
de Zeeuw, D ;
Kowey, PR ;
Shahinfar, S ;
Dickson, T ;
Crow, RS ;
Parving, HH .
DIABETOLOGIA, 2005, 48 (10) :1980-1987
[8]
Brust G. E., 1988, American Journal of Alternative Agriculture, V3, P19, DOI 10.1017/S0889189300002083
[9]
Carabello B A, 1995, J Heart Valve Dis, V4 Suppl 2, pS132
[10]
VALUE OF ECHOCARDIOGRAPHIC MEASUREMENT OF LEFT-VENTRICULAR MASS IN PREDICTING CARDIOVASCULAR MORBID EVENTS IN HYPERTENSIVE MEN [J].
CASALE, PN ;
DEVEREUX, RB ;
MILNER, M ;
ZULLO, G ;
HARSHFIELD, GA ;
PICKERING, TG ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) :173-178